Variation in cancer care is seen. Care for the same disease can differ between hospital A and hospital B. The question is: does this matter? Does the variation influence the quality of care, the course of disease, survival, quality of life or health care costs? In case guidelines have clear recommendations that one treatment is preferred over the other, then variation is unwanted. Though before starting improvement programs, the cause of the variation has to be clear; is it due to the fitness of wish of the patient to deviate from the guideline?
Variation can also develop because the recommendations in the guidelines are not always evidence based and we are not sure which care leads to the best result. Variation in care and the effect can be compared and can lead to new insights which treatment is best suitable to which patient. Moreover cancer care will be personalised to the individual patient by the use of new technologies such as the determination of the genetic profile, better imaging or detection of circulating tumour cells in blood. What effect do these new technologies and treatment modalities have on the choice of treatment, follow-up and outcome of the patient? How do we apply these (new) technologies in daily practice? How will care givers and patients be supported in their choice for a treatment or follow-up pathway? To obtain answers to these questions the University of Twente and the Netherlands Comprehensive Cancer Organisation (IKNL) have established the chair: "Outcomes research and personalised cancer care". The chair will be held by Prof Dr. S.Siesling. Preceding her inaugural lecture on 24 September an afternoon symposium will be held at the University of Twente, Enschede, The Netherlands.
Prof. Peter Huijgens, MD, director Netherlands Comprehensive Cancer Organisation (IKNL)
Prof. Peter Huijgens, director Netherlands Comprehensive Cancer Organisation (IKNL)
World-wide differences in cancer survival: the CONCORD-2 study
Prof. Michel Coleman, MD (epidemiologist, London School of Hygiene and Tropical Medicine, London, UK)
Personalized care for rare cancers: centres of expertise
Dr. Gemma Gatta, MD (epidemiologist, Istituto Nazionale dei Tumori, Milano, Italy)
Is clinical auditing influencing clinical practice?
Dr. Thijs van Dalen, MD (surgeon, Diakonessen ziekenhuis Utrecht, the Netherlands, chair NABON Breast Cancer Audit)
Personalized medicine: the Netherlands Breast Cancer project
Prof. Sabine Lin, MD, (medical oncologist, NKI-AVL, Amsterdam, The Netherlands)
Technology and personalized care: to what prize?
Prof. Maarten IJzerman (HTA, University of Twente, Enschede)
More information on the HTSR website.
You can subscribe for the symposium and the inaugural lecture at
The following day, the 25th September, the Federaday2015 will be organised having the theme: Cancer and Numbers. More information and subscription at the website .